- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
The prostate-specific membrane antigen positron emission tomography (PSMA PET) agent 64Cu-SAR-bisPSMA has now been granted a second fast track designation by the Food and Drug Administration (FDA) for prostate cancer (PCa) imaging.
The PET agent’s latest FDA fast track designation, for biochemical PCa recurrence in patients who have had definitive therapy, comes five months after the initial fast track designation for suspected metastasis in patients who are candidates for definitive PCa treatment, according to Clarity Pharmaceuticals, the developer of 64Cu-SAR-bisPSMA.
Here one can see a comparison of the PET agents 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT. The FDA has granted two fast track designations for 64Cu-SAR-bisPSMA with the latest one being for biochemical prostate cancer recurrence in patients who have had definitive therapy. (Images courtesy of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).)
"Receiving the second (fast track designation) for 64Cu-SAR-bisPSMA and well within the 60-day period following our application submission, reserved by the U.S. FDA for review, is yet another significant milestone in our bisPSMA program,” noted Alan Taylor, Ph.D., the executive chairperson of Clarity Pharmaceuticals. “This highlights the high unmet need for novel diagnostics in prostate cancer and the high quality of data we presented to the FDA.”
Emphasizing the increased uptake of 64Cu-SAR-bisPSMA in PCa lesions, Clarity Pharmaceuticals noted that recent research has demonstrated the ability of 64Cu-SAR-bisPSMA to diagnose recurrent lesions in the 2 mm range months before detection by other PSMA PET agents.
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
